Insulet (NASDAQ: PODD) recently received a number of ratings updates from brokerages and research firms:
- 11/18/2026 – Insulet was downgraded by Stifel Nicolaus from “buy” to “hold”. They now have a $165.00 price target on the stock, down from $180.00.
- 11/17/2026 – Insulet was upgraded by Zacks Research from “hold” to “strong-buy”.
- 11/9/2026 – Insulet had its “hold” rating reaffirmed by Truist Financial. They now have a $160.00 price target on the stock, up from $153.00.
- 11/7/2026 – Insulet was upgraded by Wall Street Zen from “hold” to “buy”.
- 11/6/2026 – Insulet had its price target raised by Barclays from $150.00 to $165.00. They now have an “equal weight” rating on the stock.
- 11/5/2026 – Insulet had its price target raised by UBS Group from $150.00 to $171.00. They now have a “neutral” rating on the stock.
- 11/5/2026 – Insulet had its price target raised by JPMorgan Chase & Co. from $152.00 to $170.00. They now have a “neutral” rating on the stock.
- 11/5/2026 – Insulet had its price target raised by Citigroup from $150.00 to $170.00. They now have a “neutral” rating on the stock.
- 11/5/2026 – Insulet had its price target raised by Leerink Partners from $143.00 to $167.00. They now have a “market perform” rating on the stock.
- 11/5/2026 – Insulet had its price target raised by Royal Bank Of Canada from $160.00 to $180.00. They now have an “outperform” rating on the stock.
- 11/5/2026 – Insulet had its price target raised by Sanford C. Bernstein from $175.00 to $200.00. They now have an “outperform” rating on the stock.
- 11/5/2026 – Insulet had its price target raised by Wells Fargo & Company from $144.00 to $172.00. They now have an “equal weight” rating on the stock.
- 11/4/2026 – Insulet had its “buy” rating reaffirmed by Jefferies Financial Group. They now have a $200.00 price target on the stock.
- 11/4/2026 – Insulet had its “hold” rating reaffirmed by TD Cowen.
- 10/24/2026 – Insulet was downgraded by Wall Street Zen from “buy” to “hold”.
- 10/12/2026 – Insulet had its price target lowered by Jefferies Financial Group from $275.00 to $190.00. They now have a “buy” rating on the stock.
- 10/10/2026 – Insulet was upgraded by Wall Street Zen from “hold” to “buy”.
- 10/7/2026 – Insulet was upgraded by Barclays to “hold”.
- 10/6/2026 – Insulet is now covered by Barclays. They set an “equal weight” rating and a $150.00 price target on the stock.
- 9/21/2026 – Insulet had its “sell (d+)” rating reaffirmed by Weiss Ratings.
Insulet Price Performance
NASDAQ:PODD traded down $2.75 during trading hours on Thursday, hitting $137.23. The company’s stock had a trading volume of 1,553,039 shares, compared to its average volume of 1,402,323. Insulet Corporation has a twelve month low of $126.40 and a twelve month high of $354.88. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.51 and a quick ratio of 1.83. The stock has a fifty day simple moving average of $142.20 and a 200-day simple moving average of $171.85. The company has a market capitalization of $9.52 billion, a P/E ratio of 22.35, a PEG ratio of 1.07 and a beta of 1.06.
Insulet (NASDAQ:PODD – Get Free Report) last issued its earnings results on Wednesday, November 4th. The medical instruments supplier reported $1.99 EPS for the quarter, topping the consensus estimate of $1.59 by $0.40. The firm had revenue of $842.00 million during the quarter, compared to the consensus estimate of $832.63 million. Insulet had a return on equity of 31.76% and a net margin of 13.44%. The business’s quarterly revenue was up 19.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.24 earnings per share. On average, analysts anticipate that Insulet Corporation will post 6.76 EPS for the current fiscal year.
Insulet Corporation is a medical device company focused on insulin delivery for people with diabetes. Founded in 2000, the company developed the Omnipod platform, which delivers insulin through a small, wearable pod without the tubing used by many traditional insulin pumps. Its products include Omnipod DASH and Omnipod 5, an automated insulin delivery system that can adjust insulin delivery based on glucose readings from compatible continuous glucose monitors. Insulet also provides related controllers, mobile app features, supplies and customer support.
Read More
- Five stocks we like better than Insulet
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Insulet Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet Corporation and related companies with MarketBeat.com's FREE daily email newsletter.
